Back to News
Market Impact: 0.3
Simcere Zaiming signe un accord de licence exclusif avec Roche pour le développement mondial du SIM0660
Source: PR Newswire
Healthcare & BiotechM&A & RestructuringCompany Fundamentals
Simcere Zaiming (filiale de Simcere, 2096.HK) a signé un accord de licence mondial exclusif avec Roche pour le développement et la commercialisation de SIM0660 (un anticorps trispécifique). L’annonce est globalement positive pour le pipeline/les perspectives de revenus du programme, mais sans éléments chiffrés publiés (montants, jalons ou calendrier) pouvant impacter fortement le prix à court terme.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Palantir patient data tech rejected by many NHS trusts in England
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated